REG - Cambridge Cognition - Change of Auditor

Cambridge Cognition HoldingsAnnouncement

Yesterday 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251105:nRSE1927Ga&default-theme=true

RNS Number : 1927G  Cambridge Cognition Holdings PLC  05 November 2025

5 November 2025

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Change of Auditor

 

Cambridge Cognition Holdings plc (AIM:COG), the brain health software group
specialising in digital health products that advance brain health research and
treatment, announces the appointment of Cooper Parry Group Limited ("Cooper
Parry") as the Company's new external auditor following a competitive audit
tender process.  The Company also announces that as a result of the process
Crowe UK LLP ("Crowe") has resigned as the Company's auditor.

 

Cooper Parry will conduct the audit of the Company's financial statements for
the financial period to 31 December 2025 and a proposal to re-appoint Cooper
Parry as auditors of the Company will be subject to the approval of
shareholders at the 2026 Annual General Meeting.

 

Crowe has been the auditor for the Company since 2023. Crowe has confirmed to
the Company that there are no matters connected with their ceasing to hold
office that need to be brought to the attention of the members or creditors of
the Company for the purposes of section 519 of the Companies Act 2006.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                  Tel: 01223 810700

 Rob Baker, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Ronald Openshaw, Chief Financial Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Will Goode / Mark Rogers / Freddy Crossley        (Corporate Finance)

 Rupert Dearden                                    (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)            Tel: 020 3903 7715

 David Poutney / Amber Higgs

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·    Clinical Studies for new pharmaceuticals;

·    Academic Research for scientists to understand CNS disorders;

·    Healthcare to provide physicians with cognitive assessments to allow
them to diagnose and treat patients; and,

·    Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPKZMGMRDZGKZM



            Copyright 2019 Regulatory News Service, all rights reserved